Atreca holds off development on its only clinical program, cuts headcount by 40%
11 Aug 2023
ADCPhase 1Clinical Trial Termination
In a bid to extend its cash runway, Atreca has suspended the clinical development of its solid tumor monoclonal antibody ATRC-101, slashing staff numbers by 40%. The company will focus on its preclinical antibody-drug conjugate (ADC) assets instead.
The San Carlos, CA biotech’s Phase Ib ATRC-101 was the most advanced candidate in its six-asset pipeline, three of which are ADCs. One of its ADCs will be selected as a clinical candidate in the coming months, with a possible IND submission late next year at the earliest.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.